149 related articles for article (PubMed ID: 2733597)
1. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Fürer E
Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Furer E; Sadoff JC; Germanier R
Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
[TBL] [Abstract][Full Text] [Related]
3. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
Cryz SJ; Lang AB; Sadoff JC; Germanier R; Fürer E
Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Ohman D; Fürer E
J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
Cryz SJ; Cross AS; Sadoff JC; Fürer E
Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Que JO; Cross AS; Fürer E
Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
Cryz SJ; Sadoff JC; Cross AS; Fürer E
Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
[No Abstract] [Full Text] [Related]
9. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Sadoff JC; Germanier R
Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
[No Abstract] [Full Text] [Related]
10. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma.
Campbell WN; Hendrix E; Cryz S; Cross AS
Clin Infect Dis; 1996 Jul; 23(1):179-81. PubMed ID: 8816151
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
Lang AB; Fürer E; Schürch U; Cross AS; Larrick JW; Cryz SJ
Dev Biol Stand; 1990; 71():121-6. PubMed ID: 1698165
[TBL] [Abstract][Full Text] [Related]
15. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
16. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
17. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1984 Mar; 43(3):795-9. PubMed ID: 6698608
[TBL] [Abstract][Full Text] [Related]
18. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
Pier GB; Bennett SE
J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.
Cryz SJ; Sadoff JC; Fürer E
Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]